GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.